14 April 2016 - The SMC has announced forthcoming submissions for the following medicines: aflibercept (Eylea), alirocumab (Praluent), budesonide (Cortiment), diamorphine hydrochloride (Ayendi), idarucizumab (Praxbind), nivolumab (Opdivo), olaparib (Lynparza), paliperidone palmitate (Trevicta) and progesterone (Lutigest).

For more details, go to: http://www.scottishmedicines.org.uk/SMC_Advice/Forthcoming_Submissions/Forthcoming_Submissions?iru=2ICSSBDQBC